How does Teduglutide (Gattex / Revestive) work?
Recombinant analog of GLP-2, a hormone that promotes intestinal epithelial growth and absorption. Different receptor than GLP-1 (different family). FDA-approved for short bowel syndrome. In plain terms, Teduglutide (Gattex / Revestive) is a gut drug that helps people with short bowel syndrome absorb more nutrients. A recombinant GLP-2 analog, FDA-approved in 2012 for short bowel syndrome with intestinal failure; it hits a different receptor and indication than the GLP-1 weight-loss drugs. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Short bowel syndrome patients on parenteral nutrition
- Intestinal-failure recovery contexts
- Educational reference for the GLP-2 vs GLP-1 distinction
References
- Teduglutide for the Treatment of Short Bowel Syndrome — Schwartz LK et al., NEJM, 2012
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure — Jeppesen PB, Pertkiewicz M, Messing B, et al. — Gastroenterology, 2012 (STEPS trial)
- GATTEX (teduglutide) for injection — FDA Prescribing Information — FDA / DailyMed (Takeda)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Teduglutide (Gattex / Revestive)
Last updated 2026-06-06.